ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 109 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.13 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $451,350 | -78.5% | 85,000 | -61.4% | 0.01% | -81.1% |
| Q2 2023 | $2,096,600 | +172.3% | 220,000 | +214.3% | 0.04% | +146.7% |
| Q1 2023 | $770,000 | -81.1% | 70,000 | -74.6% | 0.02% | -76.6% |
| Q4 2022 | $4,084,800 | +228.9% | 276,000 | +324.6% | 0.06% | +276.5% |
| Q3 2022 | $1,242,000 | +4.2% | 65,000 | +16.3% | 0.02% | 0.0% |
| Q2 2022 | $1,192,000 | +210.4% | 55,910 | +202.2% | 0.02% | +325.0% |
| Q4 2021 | $384,000 | – | 18,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |